COMMITMENTS AND CONTINGENCIES (Details)		1 Months Ended				12 Months Ended
	Dec. 30, 2021 USD ($) shares	May 31, 2023 USD ($)	Aug. 31, 2022 USD ($) product	Dec. 31, 2021 USD ($)	Dec. 31, 2016 USD ($) product	Dec. 31, 2023 USD ($) shares	Dec. 31, 2022 USD ($) shares	Dec. 31, 2021 USD ($)	Dec. 31, 2018 USD ($)
Loss Contingencies [Line Items]
Common stock, shares issued (in shares) | shares						70,691,992	70,466,885
Research and development						$ 28,587,884	$ 24,618,399
License agreement milestone payments (up to)	$ 203,000,000
Research plan and budget, expected costs		$ 3,500,000	$ 3,000,000
Severance payments and benefits eligibility following termination period						2 years
License Agreement
Loss Contingencies [Line Items]
Developmental milestone approvals, number of products (at least) | product			3
Advance written notice required to terminate agreement						90 days
License Agreement | Maximum
Loss Contingencies [Line Items]
License agreement milestone payments (up to)			$ 452,000,000
Northwestern University | License Agreement
Loss Contingencies [Line Items]
Upfront non-creditable one-time license issuance fee payment					$ 75,000
Annual license maintenance fee payable									$ 20,000
Royalty obligation period					10 years
Minimum number of product covered under license agreement | product					1
Northwestern University | License Agreement | Maximum
Loss Contingencies [Line Items]
Consideration payable for rights grant (up to)									$ 5,300,000
AstraZeneca
Loss Contingencies [Line Items]
Upfront cash payment				$ 5,000,000
Common stock, shares issued (in shares) | shares	7,300,000
Period preceding date of transaction				30 days
Research and development								$ 12,300,000
Lundbeck
Loss Contingencies [Line Items]
First payment due upon completion of first phase	$ 3,000,000